Skip to navigation

Non-Small Cell Lung Cancer

Image: MGCD265

The targeting of defined genetic mutations that drive lung cancer progression has proven to be an effective treatment strategy in lung cancer. A number of cancer centers routinely analyze the DNA of lung cancer cells as part of the diagnosis and treatment strategy. This increase of genomic information has led to the discovery of more genetic mutations that may be drivers of lung cancer, which has opened doors to new approaches to treatment aimed specifically at those genetic mutations.

Mirati has two drug candidates in clinical trials to test the safety and efficacy of those candidates in patients with non-small cell lung cancer.

Indications: Non-Small Cell Lung Cancer
Drug Candidate: MGCD265
 
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of MGCD265 as a treatment for non-small cell lung cancer patients whose tumors carry genetic alterations of MET and Axl. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if selected mutations are present before enrolling in the clinical trial.



Indications: Non-Small Cell Lung Cancer
Drug Candidate: MGCD516
 
Driver Mutations: Trk, RET, DDR

A Phase 1 study evaluating the effects of MGCD516 as a treatment for patients with non-small cell lung cancer whose tumors carry genetic alterations of Trk Family, RET and DDR. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before patients enroll in the clinical trial.

Find an Active Trial

Other Trials